Drug Sales In The Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche And Cephalon

Posted by rob on September 25, 2010 under Uncategorized | Comments are off for this article

Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the leukemia market will be driven mostly by chronic myelogenous leukemia (CML) therapies (Novartis’s Gleevec and Tasigna and Bristol-Myers Squibb’s Sprycel) and chronic lymphocytic leukemia (CLL) therapies (Biogen Idec/Roche’s Rituxan and Cephalon’s Treanda) until 2015, when patent and orphan-drug exclusivities of key brands will impact the sustainability of this growth… (Source: Health News from Medical News Today)
More